Sugi Predict

Sugi Predict / Compounds / SCHEMBL4067449

SCHEMBL4067449

SCHEMBL4067449

O=C(NCc1ccccc1)c1ccc(Cl)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 1.00
▸ RAB9A P51151 2/20 0.74
▸ NPC1 O15118 1/20 0.74
▸ SMN1; SMN2 Q16637 1/20 0.74
▸ HPGDS O60760 5/20 0.68
▸ CACNA1B Q00975 1/20 0.63
▸ APBA1 Q02410 1/20 0.63
▸ ALOX15 P16050 1/20 0.61
▸ LMNA P02545 2/20 0.59
▸ HDAC2 Q92769 1/20 0.58
▸ HDAC8 Q9BY41 1/20 0.58
▸ HDAC6 Q9UBN7 1/20 0.58
▸ EPHX2 P34913 1/20 0.56
▸ HPGD P15428 1/20 0.55
▸ ROCK2 O75116 1/20 0.55
▸ RPS6KA5 O75582 1/20 0.55
▸ MAP4K4 O95819 1/20 0.55
▸ PRKCG P05129 1/20 0.55
▸ PRKACA P17612 1/20 0.55
▸ RPS6KB1 P23443 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023556 0.92 L3MBTL1 (0.84) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL27822779 0.90 L3MBTL1 (0.81) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL16343160 0.88 L3MBTL1 (0.78) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL27841827 0.86 L3MBTL1 (0.76) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL13210567 0.86 L3MBTL1 (0.76) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL23063879 0.86 L3MBTL1 (0.75) L3MBTL1RAB9ANPC1SMN1; SMN2CACNA1B
SCHEMBL31253074 0.86 L3MBTL1 (0.75) L3MBTL1RAB9ANPC1SMN1; SMN2CACNA1B
SCHEMBL5083105 0.85 L3MBTL1 (0.74) L3MBTL1RAB9ANPC1SMN1; SMN2CACNA1B
SCHEMBL28443041 0.85 L3MBTL1 (0.74) L3MBTL1RAB9ANPC1SMN1; SMN2HPGDS
SCHEMBL7703395 0.85 RAB9A (1.00) L3MBTL1RAB9ANPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 — — US disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
WO-2025072151-A1 SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF BAYLOR UNIVERSITY (US) 2025-04-03 — — WO disclosed
US-20250100984-A1 SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF BAYLOR UNIVERSITY (US) 2025-03-27 — — US disclosed
WO-2024157014-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed
US-10407409-B2 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-09-10 — — US disclosed
US-20180186772-A1 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD TAKEDA CALIFORNIA, INC. 2018-07-05 — — US disclosed
EP-3336084-A1 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2018-06-20 — — EP disclosed
US-20020035094-A1 Substituted pyridine compounds and methods of use AMGEN INC. 2002-03-21 — — US disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 — — US disclosed
US-6303790-B1 REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND HOFFMAN-LA ROCHE INC. 2001-10-16 — — US disclosed
US-6297375-B1 4-phenyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2001-10-02 — — US disclosed
CN-1297887-A Process for producing pyridine derivate HOFFMANN LA ROCHE (CH) 2001-06-06 — — CN disclosed
EP-1103546-A1 Process for preparation of pyridine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-05-30 — — EP disclosed
US-6184237-B1 Substituted pyridine compounds and methods of use AMGEN INC. 2001-02-06 — — US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 — — EP disclosed
US-6022884-A PROPHYLAXIS OR TREATMENT OF INFLAMMATION AMGEN INC. (US) 2000-02-08 — — US disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027096-A1 PHD INHIBITORS HIF1AN, HIF1A, EGLN1 L3MBTL1 215/4885RAB9A 3489/4885NPC1 2583/4885
US-20180186772-A1 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD HIF1AN, EGLN3, EGLN2 L3MBTL1 4653/4885RAB9A 3346/4885NPC1 1004/4885
US-20250100984-A1 SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF ADH1A, ADH5, ADH1C L3MBTL1 2418/4885RAB9A 3192/4885NPC1 3519/4885
US-20020035094-A1 Substituted pyridine compounds and methods of use IL1B, IL6, IL1A L3MBTL1 2549/4885RAB9A 2767/4885NPC1 2800/4885
US-10407409-B2 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD HIF1AN, EGLN3, EGLN2 L3MBTL1 4653/4885RAB9A 3346/4885NPC1 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.